🔗 Share this article

This year's prestigious award in medical science has been granted for transformative findings that clarify how the immune system targets harmful infections while sparing the body's own cells.

Three renowned scientists—from Japan Shimon Sakaguchi and US scientists Mary Brunkow and Dr. Ramsdell—share this accolade.

The work identified unique "security guards" within the immune system that eliminate malfunctioning defense cells capable of attacking the organism.

These discoveries are now enabling new therapies for immune disorders and cancer.

These winners will share a prize fund valued at 11m Swedish kronor.

Decisive Findings

"The research has been essential for comprehending how the immune system functions and why we don't all suffer from severe self-attack conditions," stated the head of the Nobel Committee.

This trio's studies explain a fundamental mystery: In what way does the immune system protect us from numerous invaders while leaving our own tissues unharmed?

The immune system employs immune cells that search for signs of infection, even viruses and germs it has never encountered.

Such cells employ detectors—called recognition units—that are produced by chance in countless combinations.

That gives the immune system the capacity to fight a wide array of threats, but the unpredictability of the mechanism unavoidably creates white blood cells that can target the host.

Protectors of the Body

Scientists earlier understood that a portion of these harmful defense cells were eliminated in the thymus—the site where white blood cells develop.

The latest Nobel Prize honors the discovery of regulatory T-cells—described as the body's "security guards"—which travel through the body to disarm any immune cells that attack the healthy cells.

We know that this mechanism malfunctions in self-attack conditions such as juvenile diabetes, multiple sclerosis, and RA.

The prize committee added, "The discoveries have established a new field of research and accelerated the development of innovative treatments, for example for tumors and immune disorders."

In cancer, T-regs block the system from fighting the growth, so research are focused on reducing their quantity.

In autoimmune diseases, experiments are testing boosting T-reg cells so the organism is not being harmed. A comparable approach could also be effective in reducing the chances of transplanted organ failure.

Innovative Studies

Prof Sakaguchi, of Osaka University, conducted tests on rodents that had their immune gland extracted, leading to autoimmune disease.

He showed that introducing defense cells from other mice could stop the illness—implying there was a mechanism for blocking defenders from attacking the host.

Dr. Brunkow, from the a research center in Seattle, and Dr. Ramsdell, now at a biotech firm in San Francisco, were investigating an inherited autoimmune disease in mice and people that led to the identification of a gene critical for the way T-regs function.

"Their groundbreaking research has uncovered how the immune system is kept in check by regulatory T cells, stopping it from mistakenly targeting the body's own tissues," commented a prominent physiology expert.

"This work is a striking example of how basic biological research can have broad implications for public health."